文献速递治疗药物监测与药物基因组学特殊人群用药

哌潘普隆在儿童青少年中的群体药代动力学与疗效及副作用的关系

Pipamperone Population Pharmacokinetics Related to Effectiveness and Side Effects in Children and Adolescents.
PubMed 文献 · Clin Pharmacokinet · 2020-01-01

该研究在荷兰和德国儿童青少年中建立哌潘普隆群体药代动力学模型,发现表观分布容积416 L/70 kg、表观清除率22.1 L/h/70 kg,并按体重进行异速生长校正。应答者谷浓度中位数98.0 µg/L高于非应答者58.0 µg/L但未达统计学显著(p=0.14)。模拟显示每日两次0.6 mg/kg按体重给药优于固定剂量。

要点

  • 哌潘普隆儿童群体药代动力学参数:表观分布容积416 L/70 kg,表观清除率22.1 L/h/70 kg。
  • 应答者谷浓度中位数98.0 µg/L高于非应答者58.0 µg/L,但差异不显著(p=0.14)。
  • 儿童行为问题的治疗参考范围可能低于成人精神病性症状推荐的100-400 µg/L。

核心结论

  • 儿童青少年哌潘普隆治疗参考范围可能低于成人精神病性症状推荐的100-400 µg/L。
  • 儿童青少年使用哌潘普隆时应考虑体重进行剂量调整。

研究设计与样本

  • 前瞻性自然观察试验纳入荷兰儿童患者8例,治疗药物监测服务纳入德国儿童患者22例,共70个浓度用于NONMEM群体药代动力学建模。
  • 另从同一德国治疗药物监测服务随机抽取21例患者共33个浓度进行外部验证。
  • 模拟确定最佳剂量,并将药代动力学参数与临床改善、镇静和锥体外系症状关联。

主要发现

  • 一室模型显示表观分布容积416 L/70 kg,表观清除率22.1 L/h/70 kg,采用异速生长校正体重差异。
  • 模型成功通过外部验证。
  • 应答者谷浓度中位数98.0 µg/L(25-75百分位56.0-180.5 µg/L)数值上高于非应答者58.0 µg/L(14.9-105.5 µg/L),但无统计学显著性(p=0.14)。
  • 每日两次0.6 mg/kg按体重给药比固定剂量更能达到应答者观察到的浓度范围。

关键数值与推荐

  • 应答者谷浓度中位数98.0 µg/L(25-75百分位56.0-180.5 µg/L),非应答者58.0 µg/L(14.9-105.5 µg/L),p=0.14。
  • 成人精神病性症状推荐的哌潘普隆治疗参考范围为100-400 µg/L。
  • 每日两次0.6 mg/kg按体重给药方案在模拟中优于固定剂量。

临床怎么用

  • 儿童青少年哌潘普隆 dosing 应按体重计算,可考虑每日两次0.6 mg/kg方案。
  • 治疗药物监测时儿童行为问题的目标谷浓度可能低于成人100-400 µg/L的参考范围。
  • 需结合疗效和锥体外系症状、镇静等副作用个体化调整剂量。

局限性

  • 研究为自然观察性设计,浓度与疗效及副作用的关联需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pipamperone is a frequently prescribed antipsychotic in children and adolescents in the Netherlands, Belgium, and Germany. However, pediatric pharmacokinetics and the relationship with side effects and efficacy are unknown. Currently, divergent pediatric dosing recommendations exist. OBJECTIVES: The objective of this study was to describe the population pharmacokinetics of pipamperone in children and adolescents; to correlate measured and predicted pipamperone trough concentrations and predicted 24-h area under the curves with effectiveness, extrapyramidal symptoms, and sedation; and to propose dose recommendations based on simulations. METHODS: Pipamperone concentrations were collected from Dutch pediatric patients in a prospective naturalistic trial (n = 8), and German pediatric patients in a therapeutic drug monitoring service (n = 22). A total of 70 pipamperone concentrations were used to develop a population pharmacokinetic model with non-linear mixed-effects modeling (NONMEM®). Additionally, an additional random sample of 21 German patients with 33 pipamperone concentrations from the same therapeutic drug monitoring service was used for external validation. Pharmacokinetic parameters were related to clinical improvement, sedation, and extrapyramidal symptoms. Simulations were performed to determine optimal dosages. RESULTS: In a one-compartment model, the apparent volume of distribution was 416 L/70 kg and the apparent clearance was 22.1 L/h/70 kg. Allometric scaling was used to correct for differences in bodyweight. The model was successfully externally validated. The median [25th-75th percentile] measured pipamperone trough concentrations were numerically higher in responders (98.0 µg/L [56.0-180.5 µg/L]) than in non-responders (58.0 µg/L [14.9-105.5 µg/L]), although non-significant (p = 0.14). A twice-daily 0.6-mg/kg dosage was better than a fixed dosage to attain the concentration range observed in responders. CONCLUSIONS: Our findings suggest that pipamperone therapeutic reference ranges may be lower for children with behavioral problems than recommended for adults with psychotic symptoms (100-400 µg/L). When dosing pipamperone in children and adolescents, bodyweight should be taken into account.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Kloosterboer SM, Egberts KM, de Winter BCM, et al. Pipamperone Population Pharmacokinetics Related to Effectiveness and Side Effects in Children and Adolescents. Clin Pharmacokinet. 2020. PMID: 32394297. doi:10.1007/s40262-020-00894-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。